Clinical trial · no report yet · Phase 2
NCT06661915
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- NCT06661915 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Accelerated Phase Myeloproliferative Neoplasm; Blast Phase Myeloproliferative Neoplasm; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Not Otherwise Specified; Polycythemia Vera; Primary Myelofibrosis; Secondary Myelofibrosis
- Interventions
- Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Decitabine and Cedazuridine; Iadademstat
- Arms
- Arm I (ASTX727) · Experimental
- Arm II (ASTX727, iadademstat) · Experimental
- Enrollment
- 78 (estimated)
- Primary outcomes
- Acute leukemia response-complete (ALR-C) rate
- Sponsor
- National Cancer Institute (NCI)
- Start
- Aug 14, 2025
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06661915 · updated Sep 30, 2026